Pathogen Inactivation of Labile Blood Products
Blood Transfusion and Histocompatibility
Description:... Methods aimed at inactivation of pathogens in labile blood products have been developed in recent years. Their use raises a number of issues, including efficiency, the damage inflicted to the blood products, the toxicity for patients, and the cost-benefit ratio. In the foreseeable future, national blood transfusion services and health authorities will have to consider the introduction of these methods. The report summarises the current information on these pathogen inactivation procedures.
Show description